Abstract: A large overdose of insulin is a serious health matter. Information concerning administration and duration of intravenous (IV) glucose, other treatment options or complications besides hypoglycaemia following large insulin overdoses is not readily apparent from the literature. A systematic search, compilation and review of case reports on insulin overdoses, published 1986-2017, was performed in PubMed, EMBASE, Cochrane and PROSPERO databases. Of 1523 published articles, 45 cases of insulin overdoses were included with a total median insulin dose of 900 international units (IU) (range 26-4800 IU). Hospitalization occurred in 44 cases with a median hospitalization duration of 94 hr (range 12-721 hr), and one-third (n = 15) admitted to the intensive care unit. First-line treatment was IV glucose treatment in 95% of cases. Treatment options besides IV glucose that were reported beneficial included glucagon IV or intramuscular (IM), octreotide IV or IM, surgical excision, hydrocortisone IV and oral intake of complex carbohydrates. Prevalent complications were intermittent cerebral impairment (73%), hypokalaemia (49%), other electrolyte disturbances (42%), and hepatic disturbances (7%) and cardiac toxicity (e.g. cardiac arrhythmia) (9%). Long-term consequences were one case of lasting hypoglycaemic encephalopathy and one death. In conclusion, following large insulin overdoses, in-hospital admission and treatment with IV glucose may be needed for up to a week. Monitoring of electrolytes and hepatic and cardiac functions seems important. Several experimental treatment options may be considered in addition to glucose administration. With appropriate pre-and in-hospital treatment, cases with severe hypoglycaemia and neurologic complications may have a favourable outcome.
Insulins are drugs with a narrow therapeutic index that designates a small difference between the dose that causes a therapeutic effect and the dose that causes toxicity [1] [2] [3] [4] . An overdose of insulin for example due to medication errors or intentional poisonings such as suicide attempts may cause severe hypoglycaemia requiring assistance of others and in worst cases brain damage or even death [5, 6] .
Consequently, large insulin overdoses are almost always treated in a hospital setting with careful monitoring of the plasma glucose concentration and administration of intravenous (IV) dextrose to avoid the hazards of hypoglycaemia [7] [8] [9] [10] [11] . However, the scientific literature concerning the consequences and treatment of large insulin overdoses mainly consists of case reports and a few retrospective, epidemiological evaluations of data from regional poison centres with limited clinical information [12, 13] . Reviews and textbooks that summarize the recommended treatment of large insulin overdoses are quite unspecific, and, for instance, often there is little distinction in the treatment guidelines between poisoning with insulin and other antidiabetic medications, for example sulphonylureas [14] [15] [16] [17] [18] [19] . Thus, information concerning duration of IV glucose administration, treatment options or potential complications other than hypoglycaemia following large insulin overdoses is not readily apparent from the literature.
Here, we attempt to systematically search, compile and review the existing case reports on insulin overdoses with a focus on clinical course and described treatment options.
Materials and Methods
Data sources, searches and study selection. With final update in July 2017, PubMed and EMBASE were searched with the following search string: [(insulin) AND (overdose OR poisoning OR toxicology)] and the following filters: full text, human, English language. The Cochrane and PROSPERO databases were also searched, and all included articles had their reference lists reviewed. For the main data analysis, we excluded manuscripts published prior to 1986, autopsy reports, non-English language manuscripts and case reports published only as conference abstracts. The reason for excluding older manuscripts was to, preferably, obtain cases with more modern insulins that are mainly used today (i.e. short-acting and long-acting insulin analogues). Ultimately, 45 case reports [2, were included for the data extraction. Please refer to fig. 1 for a flow chart of the data inclusion, search strategy and eligibility criteria.
Data extraction and quality assessment. From case reports, we registered the following variables: age, sex, diabetes, comorbidity (cardiac, kidney, known psychiatric illness), intended overdose, insulin mono-exposure, insulin type, total insulin dose, alcohol consumption, symptoms (autonomic, light cerebral or severe cerebral), hospitalization, duration of hospitalization, intensive care unit stay, time span from overdose to arrival at hospital, blood glucose level at hospital arrival, blood glucose nadir value, duration of IV glucose administration, treatment (IV glucose, glucagon, octreotide, surgical incision, hydrocortisone and other), acute complications (hypokalaemia and other electrolyte disturbances, cardiac toxicity, other, none) and long-term complications (hypoglycaemic encephalopathy, mortality and other).
We used Zotero Reference Manager as reference manager and Microsoft Excel 10 as database.
Data synthesis and statistical analysis. Statistics were performed in Microsoft Excel 2010. Based on the available cases, categorical variables are reported as percentages of total, and continuous variables are reported as median and range values. Case reports that gave no information on a specific variable were omitted from the statistical calculations. We explored whether some of the registered variables were associated with longer duration of hospitalization. For continuous variables, we inspected scatter plots and performed simple linear regression. For categorical data, we compared hospital duration between groups with the Mann-Whitney test. Statistical significance was set at a two-tailed p-value ≤0.05.
Results
The data extracted from 45 case reports are shown in table 1. Sex distributed equally, and the median age was 36 years (range . The majority of patients had type 1 diabetes, and one-third of our cases (n = 15) had no diabetes. Established psychiatric disease was the most prevalent comorbidity and was present in approximately half (n = 21) of the cases.
Intentional overdoses posed 95% (n = 35) of the cases with 82% (n = 37) being overdoses only with insulin (i.e. combinations of various basal and bolus insulins and no other medication). The median total insulin dose was 900 international units (IU) (range 26-4800 IU). Insulin was administered subcutaneously, except in one case where it was administered IV [24] . Alcohol was consumed in relation to the overdose in 13% (n = 6) of cases.
Typically, patients had low plasma glucose at arrival, and the nadir blood glucose value was, in most cases, identical to blood glucose at arrival. Patients were hospitalized in all but one case (n = 44). The hospitalization duration ranged from 12 to 721 hr. One-third of the patients (n = 15) were admitted to the intensive care unit.
IV glucose treatment was administered in 95% (n = 41) of the cases. When stratified, isolated IV infusion of glucose was given to 36% (n = 16) and none had isolated IV bolus glucose treatment. IV glucose infusion had to be continued for up to 7 days with a median duration of 3 days. Median values of IV glucose treatment were 22 hr shorter than total hospitalization time, after which patients were discharged to psychiatric follow-up or home.
We did not find any correlation between hospitalization duration and insulin dose, arrival blood glucose or time until hospital arrival. Likewise, the presence of cerebral symptoms, intensive care unit stay and diabetes status were not associated with longer hospital admission. The only significant finding was a difference between median duration of hospitalization for isolated short-acting insulin overdoses (n = 6) versus isolated insulin glargine overdoses (n = 11) (54 hr versus 120 hr ) (p = 0.05).
The symptomatology in the cases were various degrees of cerebral impairment in 73% (n = 27) and symptoms associated with sympathetic nervous system activation in 43% (n = 16). Acute complications (n = 27) included hypokalaemia (median 3.2 mmol/l) and other electrolyte disturbances (n = 19) and cardiac toxicity (e.g. cardiac arrhythmia) (n = 4). Other acute complications only reported in one case each were acute pulmonary oedema, acute hepatitis, prolonged cerebellar ataxia, hepatic steatosis and glycogen storage hepatomegaly. Please refer to table 2 for a presentation of these unique complications as well as cardiac toxicity and electrolyte disturbances. Long-term complications were seen in two cases with one chronic encephalopathy (due to severe hypoglycaemia with a nadir blood glucose value of 0.4 mmol/l) and one death.
Besides IV glucose administration, other treatment options included glucagon (in 16% of cases, n = 7), octreotide (2%, n = 1), surgical incision (4%, n = 2), hydrocortisone treatment (2%, n = 1) and 'other' in the form of intake of various forms of oral glucose (13%, n = 6). Details concerning specific treatments in addition to IV glucose are presented in table 3. ElLaboudi et al. [44] reported an insulin intoxication monitored on a continuous glucose monitoring device.
Discussion
We performed a systematic review of case reports on insulin intoxications from the past 32 years and summarize several outcomes and treatments that may be relevant for the monitoring and care of patients presenting with intentional insulin overdoses. Almost all of the insulin doses were very high and required in-hospital IV glucose treatment with half of the patients needing IV glucose for more than 3 days. Only one case report with a non-intentional poisoning of 26 IU was treated at home [46] . Overdoses of long-acting insulins led to longer duration of hospitalization compared to short-acting insulins alone. But there was large variation between cases, and one overdose with short-acting insulin required up to 144-hr admission. Electrolyte disturbances, including hypokalaemia and hypocalcaemia, cardiac disturbances and organ toxicity, such as hepatotoxicity, were also reported. Interestingly, only two cases (6%) led to long-term consequences (one brain damage and one death), and both of these were comatose prior to hospital arrival [2, 21] .
In clinical toxicology, case reports often represent the only detailed clinical data available, and these reports are often used to disseminate novel treatment proposals, spectacular or even surprising outcomes [56] . Thus, our data should be cautiously interpreted and generalized (small sample size and large heterogeneity between case reports) and could actually be viewed upon as examples of extreme intoxications, which is reflected in the median total insulin dose of 900 IU. To our surprise, however, the characteristics of poisoned patients in this case series seem quite similar to the characteristics of a cohort derived from inquiries to a poison information centre, as reported by Von Mach et al. [12] . Compared to the poison centre population, the patients in our case cohort had similar age, sex distribution and symptomatology, frequency of intentional overdoses and risk of adverse outcomes. Further, in the data by Von Mach et al., the majority of patients also had a favourable outcome with a strikingly similar incidence of long-term adverse events, that is 3% had permanent cerebral defects and 3% died. As often is the case, the poison centre population was less well characterized and had an unknown median total insulin dose. Only one noteworthy difference exists compared to the data by von Mach et al. : We found a majority of long-acting insulin intoxications in our cases, whereas von Mach et al. reported a majority of short-acting insulin poisonings (short-acting 36% versus 56%, respectively). The difference in implicated insulins might reflect the increasing popularity of long-acting insulins. In a later publication, von Mach et al. [13] corroborated the demographic similarity to our case cohort and underlined that with ensuing correct treatment even poisonings with very high doses of insulin may have a favourable outcome (mortality and lasting cerebral defects 2-4%). This is in accordance with the more general literature (mostly on unintentional insulin overdosing) reporting that severe hypoglycaemia treated at emergency departments has a favourable outcome [57, 58] . However, it is important to distinguish between the relatively common minor overdoses and the massive intentional overdoses that were described in nearly all of our reviewed cases (and the ones presented by von Mach et al.).
In contrast to our findings mainly on large insulin overdoses, studies on unintentional, low-dose insulin overdoses have concluded that many of these can be treated at home with a low rate of adverse outcomes [59, 60] .
Prior reports that were not included in our data analysis included eight cases reported by Arem and Zoghbi in 1985 [61] . Their conclusions support our findings on an overweight of persons with diabetes and known psychiatric illness, hypoglycaemia stretching over several days and finally a possible impact on duration of hospitalization by insulin type and dose.
Treatments.
In accordance with the only firm textbook advice [14, 15] , IV glucose was administered as first-line treatment in nearly all cases. Interestingly, other treatment options such as the use of glucagon, octreotide, surgical incision, hydrocortisone and oral intake of complex carbohydrate solutions were also reported beneficial for some patients. There was a lack of pattern in the use of these adjunct therapies, which is likely a consequence of the fact that most of these therapies are not even mentioned in leading textbooks [14, 15] . One should note the important Only four case reports mentioned cardiac complications, and all of them were likely secondary to either electrolyte disturbances or co-ingestion of cardio-depressive medication (i.e. bradycardia [55] after propranolol 2 g and digoxin 25 mg or sustained hypotension [38] after 500 mg metoprolol and >5 tablets isosorbide dinitrate tablets) QTc prolongation and sinus tachycardia occurred together with hypokalaemia (2.7 mmol/l) in one case [54] . Unspecified cardiac arrhythmia appeared once with the case report giving scarce clinical information and no information on treatment [2] Myocardial infarction was reported in an unobtainable case report [70] Full recovery beside the person with unspecified cardiac arrhythmia who suffered permanent cerebral defects due to hypoglycaemia Hepatic adverse event
Acute hepatitis [20] Hepatic steatosis [35] Glycogen storage hepatomegaly [22] Acute hepatitis and hepatomegaly were associated with large amounts of IV 1 glucose as part of the antihypoglycaemic treatment in three case reports In one case [35] , the estimated IV glucose loads were 1200-1400 g daily during the first three days of treatment which led to hepatic steatosis (estimated by ultrasound) In the case with acute hepatitis [12] (estimated by increases in plasma aminotransferases), surgical excision of the insulin injection site corrected the blood sugar and liver function tests returned to normal Glycogen storage hepatomegaly [14] resolved itself following glycaemic stabilization
In all cases hepatic status spontaneously returned to normal Acute pulmonary oedema [21] Acute pulmonary oedema was reported in a comatose patient with signs of brain damage at arrival. The authors speculated if the acute pulmonary oedema could be related to the insulin overdose due to neurogenic and metabolic causes Death 4 months after admission due to infection Prolonged cerebellar ataxia [47] Patient presented with blood glucose of 1.7 mmol/l and a neurological examination showed severe dyskinesia in all four limbs and a wide-based, unsteady gait. Thirteen weeks later, a follow-up neurological examination turned out normal Full recovery Forty-seven-year-old man with a 2100 IU mixed short-and long-acting insulin overdose. Glucagon injection intramuscularly (unknown dose) twice complementary to IV glucose treatment 6.6 mg/kg/hr kept blood glucose >5.5 mmol/ l and <11.1 mmol/l during the first 24 hr after intoxication There were no comments on efficacy or safety of glucagon Flood et al. [42] 1 mg glucagon IM Forty-six-year-old man with a mixed overdose of 4000 IU fastacting insulin and 11 mg thyroxine
The patient was reported to wake up in response to glucagon (and IV glucose) treatment Intramuscular glucagon 1 mg was given as part of the initial treatment in combination with 75 ml 50% IV glucose in response to a stuporous clinical condition El-Laboudi et al. [44] 1 mg glucagon IM and oral intake of complex carbohydrates
Twenty-five-year-old man with a 300 IU short-acting insulin overdose while wearing a continuous glucose monitoring device. Intramuscular glucagon 1 mg was given subsequently to a 10% IV glucose infusion and a 40% glucose gel administration 5 hr and 20 min. after admission in response to hypoglycaemia <4 mmol/l (raised blood glucose >6 mmol/l)
Immediate elevation of blood glucose <4 mmol/l to >6 mmol/l Efrimescu et al. [54] 1 mg glucagon IM and oral intake of complex carbohydrates A young medical professional (unknown age and sex) with a 1000 IU fast-acting insulin overdose. Pre-hospital assessment revealed a capillary glucose of 1.4 mmol/l. Oral glucose 20 g left the capillary glucose unaltered measured 15 min. later. Intramuscular glucagon 1 mg given afterwards raised capillary glucose from 1.4 mmol/l to 2.9 mmol/l. Thereafter, hypoglycaemia was avoided until hospital arrival with the help of a 250 ml 10% IV glucose bolus and a continuous infusion Glucagon 1 mg raised plasma glucose 1.5 mmol/l within the hypoglycaemic range (below 3.9 mmol/l) The authors note glucagon treatment (in combination with oral glucose) was effective in spite of chronic alcohol intake White et al. [53] Glucagon SC 3 followed by IV (15 mcg/kg/hr) Fifteen-year-old man with type 1 diabetes took an unknown dose of premixed insulin. The authors note peripherally administered, 12% IV glucose did not counteract hypoglycaemia. Glucagon SC administered each hour was only transiently effective in avoiding hypoglycaemia. To avoid a central venous catheter 12 hr after admission, glucagon was administered as a continuous IV infusion 15 mcg/kg/hr in a 5% dextrose solution in combination with continued 12% IV glucose administration
The combined glucagon IV and IV glucose treatment (with a gradual decrease in dose) kept plasma glucose >4 mmol/l until reinstatement of normal insulin therapy on day four
Garg et al. [55] 5 mg glucagon IV followed by continuous infusion 2-5 mg/hr Thirty-two-year-old man took 1600 IU fast-acting insulin together with 2 g propranolol, and 25 mg digoxin overdose. Glucagon was given at the intensive care unit following admission to the hospital initially as a 5 mg IV bolus followed by continuous IV infusion 5 mg/hr for 19 hr then lowered to 2 mg/hr for the subsequent 21 hr to prevent bradycardia due to its positive chronotropic and ionotropic effects. Hypoglycaemia was tackled by IV glucose administration High-dose glucagon was primarily administered to prevent bradycardia (due to propranolol ingestion). No comment was made on any possible synergistic antihypoglycaemic effect or adverse effects (e.g. nausea or vomiting) Groth and Banzon [38] 100 mg Octreotide x 3-4 daily SC and IV Fifty-six-year-old man with a 3300 IU overdose of long-acting insulin. Prolonged IV glucose treatment was required for >100 hr. On the fourth day of treatment with IV glucose, octreotide was administered in total eight times. First three doses of 100 mg SC every 8 hr subsequently changed to five doses of 100 mg IV every 6 hr to maximize absorption Twelve hours after octreotide treatment (day 4) was initiated, no more hypoglycaemic episodes occurred. The authors' interpretation was that the contribution of octreotide to the clinical improvement was uncertain. No safety issues were reported Bayly and Ferner [48] Hydrocortisone Sixteen-year-old woman with a 900 IU mixed-type insulin overdose. IV glucose 50% 50 ml bolus and a 5% infusion were administered. Increasing amounts of IV glucose were required by a central line. Hydrocortisone was administered (unknown dose) to induce peripheral insulin resistance. Sixty hours after admission, the patient was discharged with full recovery There were no comments on efficacy or safety of steroid treatment (continued) differential diagnosis of insulinoma when looking at insulin overdoses, diagnostics and treatment [62] . Glucagon was administered in-hospital in 16% of cases and was the most frequently used adjunct to IV glucose treatment. This is somewhat surprising as guidance actually advocates that glucagon should only be considered when IV access is not possible [14] . Glucagon counters hypoglycaemia mainly by stimulating hepatic glycogenolysis and gluconeogenesis with a following release of endogenously produced glucose to the blood. One should note the possible hepatic glucose depletion seen in alcohol-induced hypoglycaemia [63] . Nonetheless, in half of the cases, intramuscular (IM) glucagon 1 mg was reported to have a marked plasma glucose elevating effect. No adverse effects were reported, which is surprising considering the fact that supraphysiological glucagon very often causes nausea and vomiting [64, 65] . White et al. [53] used IV glucagon in a 5% dextrose solution combined with peripheral IV glucose infusion to avoid a central venous catheter in an adolescent. One case reported a special situation where glucagon may have had more beneficial effect, because it also alleviated bradycardia in the case with massive co-exposure to digoxin and metoprolol [55] . Of interest, a Biostator© Artificial Pancreas [66] was used to treat an insulin overdose in 1983 and highlight possible future treatment options with continued technological progress. As of today, our data do not support the routine use of glucagon as primary therapy. However, based on the generally favourable reports, it is recommended to use IM glucagon as bridging therapy until sufficient IV dextrose treatment is established.
Octreotide was administered in only one case to a 56-yearold man with type 2 diabetes and massive cardiovascular comorbidity with the intention to reduce the need of IV glucose treatment, as reported by Groth and Banzon [38] . Another recent case report (not included in the data analysis as it has only been published as a meeting abstract) also reported a favourable outcome to treatment with octreotide 25 lg/hr used as adjunctive therapy to IV glucose treatment in a patient without diabetes [67] . The rationale behind using Twenty-six-year-old man with a 4800 IU overdose of longacting insulin. Hypoglycaemia was countered for the first 3 days by a combination of IV glucose administration or an hourly intake of 50-100 ml undiluted fruit drink concentrate (28-55 g of glucose per drink) due to compliance problems with IV glucose treatment. On the third day, acute hepatic injury presented itself confirmed by blood tests and ultrasonography of the liver. The single-site insulin depot on the abdomen was surgically excised by a plastic surgeon on day four
Twenty-four hours after surgery (day 5), a marked fall in glucose requirements was seen together with stabilization of capillary blood glucose. Improvement in liver function test was observed as well. No insulin measurements were made. The timing of surgical incision supports the effect on hypoglycaemia and hepatic functions, the authors note the relation 'likely' McIntyre et al. [29] Surgical incision Sixteen-year-old man with a 500 IU long-acting insulin overdose. He was comatose at arrival and primarily treated with 50% glucose IV bolus. Four injection sites were visible, and the easily palpable were surgically excised Glucose infusion could be discontinued 8 hr after surgery, and patient discharged the day after.
The authors recommend surgical excision as an option in single-site injections without suggesting a threshold insulin overdose or time interval Kumar et al. [33] Oral intake of uncooked corn starch
Twelve-year-old girl with a 2000 IU overdose of long-acting insulin. Hypoglycaemia proved difficult to counter initially, but a combination of IV glucose together with a general diet (3 meals plus 3 snacks) maintained daytime glycaemia >3.8 mmol/l. However, recurrent night-time hypoglycaemia continued, and uncooked corn starch (1.5 g/kg/dose as oral slurry in cold water) was administered every third hour commencing night four
Following corn starch administration (day 4), no night-time hypoglycaemia was observed and nighttime IV glucose treatment lowered octreotide to inhibit endogenous insulin production through stimulation of pancreatic somatostatin receptors has been suggested elsewhere [31, 40] . Another included case report [48] actually illustrates graphically that non-suppressible, endogenous glucose production may be a complicating factor in insulin overdoses (in patients with preserved, endogenous insulin secretion). However, in the case by Groth and Banzon, octreotide was administered after several days of intravenous glucose, and near total absorption (and elimination) of exogenous insulin may have been more decisive for the reported resolution of need for glucose [38] . Thus, we are not convinced that it is beneficial to administer somatostatin agonists like octreotide in insulin overdoses: Somatostatin has a suppressive effect on the GI absorption and important counter-regulatory hormones such as glucagon and growth hormone [68] . Thus, in a situation with excessive insulin, octreotide may actually increase the risk of hypoglycaemia -an adverse effect that was not discussed by any of the authors reporting the successful use of octreotide. Typical side effects to octreotide treatment include nausea, flatulence, diarrhoea and injection site pain, but none was reported [38] . Surgical excision was performed in two patients [20, 29] . One had the highest reported dose of 4800 IU and acute hepatic injury; the other had 'only' taken 500 IU which was well below the median dose for all of the cases. In both situations, early local excision of a single-site insulin injection was performed. Campbell and Ratcliffe [69] were the first to report surgical excision of single-site insulin injection as a treatment option in 1982; the case report was not included in our review due to publication age. The authors noted a decrease in serum insulin levels shortly after the procedure. Considering the generally benign course even with extreme insulin doses, surgical excision should probably be considered in extreme cases (i.e. long-acting insulin doses >1500 IE) with visible, accessible infiltrates and with complications or problematic recurrent hypoglycaemia. There were no reports of needle aspiration of the injection site as suggested by a toxicology textbook [14] .
Hydrocortisone treatment was mentioned by Bayly and Ferner [48] in a case report from 1993, where it was administered to induce peripheral insulin resistance. No information was given specifically on the safety or efficacy of hydrocortisone; however, the patient fully recovered. Glucocorticoids affect glucose metabolism by reducing insulin sensitivity, that is leading to reduced glucose uptake in the liver and muscle tissue. The time frame is not entirely clear, but these metabolic effects probably take several hours to gradually develop. Nevertheless, glucocorticoids could be considered a viable treatment option worth exploring in cases of extreme insulin overdoses.
Finally, different forms of oral intake of complex carbohydrates were used in several case reports. Oral carbohydrates were used as adjunct to IV glucose boluses and IM glucagon treatment in two case reports [44, 54] and finally as an alternative to IV glucose treatment due to compliance problems [20] . Kumar et al. [33] reported the use of uncooked corn starch to combat recurrent night-time hypoglycaemia in a 12-year-old girl. The corn starch was administered on 6 the fourth night after hospital admission, whereafter the nighttime hypoglycaemic events stopped. Following commencement of uncooked corn starch on the fourth night, no further IV glucose bolus was necessary, and the continuous IV glucose dose lowered. The rationale behind the use of uncooked corn starch is slow, enzymatic cleavage of the carbohydrate polymers with a prolonged, sustained release of glucose to the blood [33] . But although this treatment option seems rational, it does not preclude cautious glucose monitoring and additional need of IV glucose. Future research on insulin overdoses that focus on exploring the clinical safety and efficacy of the mentioned treatment options is clearly warranted.
Complications.
Several complications to insulin intoxications and excess glucose treatment were reported in the 45 case presentations, as presented in table 2.
Hypokalaemia was the most prevalent complication registered. It was surprisingly mild with only a few case reports describing severe hypokalaemia <2.5 mmol/l in spite of very high insulin doses [21, 30, 54] . In two case reports, plasma concentrations of magnesium and phosphate were affected. In the first one, electrolyte levels spontaneously returned to normal [30] . In the second one, treatment with IV magnesium 2 g was initiated to correct QTc prolongation and prevent Torsade de Point Ventricular Tachycardia [54] .
Cardiac complications were reported in four cases. Besides the mentioned QT prolongation associated with concurrent hypokalaemia and hypomagnesaemia, insulin per se seemed to play a little role in the aetiology. Hypotension and bradycardia were reported in two cases with mixed overdoses including cardio-depressant drugs [38, 55] . Also, Cooper reported cardiac arrhythmia in a case with acute and chronic cerebral defects [2] . Interestingly in one case, cerebral defects presented as prolonged cerebellar ataxia that resolved itself within 14 weeks [47] . Finally, myocardial infarction was reported in one of the unobtainable articles for the data analysis [70, 71] .
The only case resulting in death was initially complicated by acute pulmonary oedema with uncertain aetiology [21] . There were also reports of hepatic abnormalities, but all of these resolved spontaneously following glycaemic stabilization. Interestingly, and perhaps expected, based on the hepatic effects of high-dose insulin, Jolliet et al. [35] reported a case of hepatic steatosis following intensive IV glucose treatment for three consecutive days. Tjuimoto et al. [22] also described a similar situation of glycogen storage hepatomegaly. Acute hepatitis was reported in one case, and the mechanism behind this seems more uncertain [20] .
Monitoring and possible prognostic factors. Interestingly, El-Laboudi et al. [44] reported an insulin overdose monitored on a continuous glucose monitoring device, a Medtronic iPro2©. The device was used six days prior to intoxication and removed one day after. The authors highlighted the limitations of the existing technology to guide therapy in the hypoglycaemic range. However, novel technologies might solve this problem. Thus, continued monitoring remains an interesting in-hospital monitoring option for insulin overdoses to identify progression towards hypoglycemia and limit the frequent and clinically burdensome blood glucose measurement from finger/earlobe or IV sampling cannula.
Megarbane et al. [72] performed a prospective journal chart study on 25 patients on an intensive care unit with the intention to identify possible prognostic factors and the importance of plasma insulin levels. They concluded that a delay in therapy >6 hr from intoxication and mechanical ventilation >48 hr were independently linked to a worsened outcome.
Strengths and limitations.
As mentioned above, case reports constitute the bulk of literature on intentional insulin overdoses, but may also be prone to publication bias, that is biased by 'extraordinary' cases. This may be beneficial if one is interested in novel treatment options, but is a limitation to the generalizability, and it should therefore be considered a major caveat when interpreting the present data. We only included case reports published within the last 32 years to get a more representative picture of overdoses with currently used insulins. We chose to exclude autopsy reports that normally have limited clinical features. Interestingly, a review by Arem and Zoghbi [61] suggested a higher mortality following insulin overdoses, and it is likely that the mentioned publication bias and exclusion of autopsy reports together with a lack of follow-up on mortality (besides what is mentioned in each case report) result in an overly optimistic mortality estimate in our results. Also, we note that almost all case reports are from Europe or North America, and we were, for example, unable to retrieve a case report from a journal from Thailand [73] .
Conclusion
The collective review of cases reporting on massive insulin overdoses suggests that in-hospital treatment with IV glucose is needed for days and up to a week. Monitoring of electrolytes (potassium, calcium, magnesium and phosphate) and hepatic and cardiac functions seems important based on the reported adverse events. Experimental treatment options (e.g. administration of complex oral carbohydrate, glucagon, glucocorticoid, surgical excision) have been used and -despite ambiguous data on efficacy and safety -may be considered in addition to glucose administration. Finally, even cases with a clinical presentation of severe hypoglycaemia and neurologic complications may have a favourable outcome with appropriate treatment pre-and in-hospital treatment.
